

## Anesthesia's Impact on Critical Care Medicine: Review Article

Mohd Husni Alqutamy\*<sup>1</sup>, Buthina Abdulla S Al Obaid<sup>2</sup>, Abdullah Oudah A Alahmari<sup>3</sup>, Aref N A M Sh Almutairi<sup>4</sup>, Milyani, Hussain Ziad H<sup>5</sup>, Abdulrahman Mohammed Assiri<sup>6</sup>, Abdouh Ali Awad<sup>7</sup>, Abdulaziz Nasser Aldawsari<sup>8</sup>, Mohammed Fahad M Abdulhadi<sup>9</sup>, Mahdi Hussain Alkhaluf<sup>10</sup>, Mahdi ali alamer<sup>11</sup>, Mohammed Abdulaziz Albulayhid<sup>12</sup>

<sup>1</sup> Anesthesia consultant, Anesthesia consultant at Bnoon, Jeddah, Saudi Arabia, Email: [Modalqutamy777@gmail.com](mailto:Modalqutamy777@gmail.com)

<sup>2</sup> Anesthesia and Critical Care Physician, King Fahad Specialist Hospital Dammam, Saudi Arabia, Email: [B\\_oo\\_si@hotmail.com](mailto:B_oo_si@hotmail.com)

<sup>3</sup> Medical Intern, King Abdulaziz University Hospital, Saudi Arabia, Email: [Abood.ahmari77@gmail.com](mailto:Abood.ahmari77@gmail.com)

<sup>4</sup> Assistant Registrar - Forensic Medicine at the General Department of Criminal Evidence, Forensic Medicine Department, Kuwait City, Kuwait, Email: [itsunclez@gmail.com](mailto:itsunclez@gmail.com)

<sup>5</sup> Medical student, Umm al-Qura University, Saudi Arabia, Email: [Hussainmelyani99@gmail.com](mailto:Hussainmelyani99@gmail.com)

<sup>6</sup> Al Oyoum City General Hospital Alahsa, Saudi Arabia, Email: [Abudasire89@gmail.com](mailto:Abudasire89@gmail.com)

<sup>7</sup> General Physician, King Salman Hospital, Riyadh, Saudi Arabia, Email: [Dr\\_Abdouh12@hotmail.com](mailto:Dr_Abdouh12@hotmail.com)

<sup>8</sup> Medical intern, King Abdulaziz University Hospital, Saudi Arabia, Email: [mohammedabdulhadi0003@gmail.com](mailto:mohammedabdulhadi0003@gmail.com)

<sup>9</sup> General Physician, King Faisal University in Alhasa, Saudi Arabia, Email: [Dr.Mahdi.Alkhaluf@gmail.com](mailto:Dr.Mahdi.Alkhaluf@gmail.com)

<sup>10</sup> Respiratory Therapist, Almoosa Hospital, Alahsa, Saudi Arabia, Email: [mahdi.ali.alamer@gmail.com](mailto:mahdi.ali.alamer@gmail.com)

<sup>11</sup> GP (general physician), King Faisal University in Alhasa, KSA, Email: [Dr.Mahdi.Alkhaluf@gmail.com](mailto:Dr.Mahdi.Alkhaluf@gmail.com)

<sup>12</sup> Pharmacist, Adam Medical Company, Qassim, KSA, Email: [Mohammedalbulhyid@gmail.com](mailto:Mohammedalbulhyid@gmail.com)

**\*Corresponding author:** Mohd Husni Alqutamy, Email: [Modalqutamy777@gmail.com](mailto:Modalqutamy777@gmail.com)

### ABSTRACT

The integration of anesthetic expertise is fundamental to critical care. This review article aims to comprehensively synthesize and evaluate the multifaceted impact of anesthesiology on the practice and outcomes of critical care medicine. It explores the physiological, pharmacological, and procedural contributions of anesthesia, from foundational principles to contemporary best practices. A narrative review of the current literature was conducted utilizing sources including peer-reviewed journals, clinical trial databases, and professional society guidelines. A comprehensive literature search was conducted in PubMed, Scopus and Embase for articles. The search combined controlled vocabulary (e.g., MeSH "Anesthesia" and "Critical Care") with key free-text terms (e.g., "perioperative care," "intensive care," "postoperative complications," "outcomes"). Evidence demonstrates that anesthetic principles directly improve outcomes through lung-protective ventilation, which reduces mortality in Acute Respiratory Distress Syndrome (ARDS); protocolized, light sedation strategies, which decrease ventilator days and the incidence of delirium; and goal-directed hemodynamic management, which mitigates organ injury. The review confirms that specific anesthetic agent selection (e.g., dexmedetomidine over benzodiazepines) and multimodal analgesia protocols significantly influence survival, complication rates, and long-term functional recovery. Furthermore, the anesthesiologist's role in perioperative care bridges the operating room and ICU, optimizing high-risk patients through Enhanced Recovery After Surgery (ERAS) pathways and structured handovers. Anesthesiology is not merely a historical contributor but a continuously evolving pillar of modern critical care. Its principles and practices are proven to enhance patient safety, reduce morbidity and mortality, and improve the quality of survival.

**Keywords:** Anesthesia, Critical Care, Intensive Care Units, Mechanical Ventilation, Sedation.

### INTRODUCTION

The modern intensive care unit (ICU) can trace its lineage directly to the postoperative recovery rooms and respiratory units established in the mid-20th century, which were largely staffed and pioneered by anesthesiologists. The most visible and immediate contribution of anesthesiology to critical care lies in the domain of airway management and respiratory support. Anesthesiologists are the unequivocal experts in securing a compromised airway, a skill that is vital in the ICU for

patients with respiratory failure, neurological depression, or sepsis. The development and refinement of techniques for rapid sequence induction and intubation, largely driven by anesthetic practice, have become the standard of care in the ICU to prevent aspiration and ensure patient safety<sup>1</sup>.

Beyond the initial intubation, the principles of mechanical ventilation, which were pioneered in the operating room (OR), are central to managing patients with acute respiratory distress syndrome (ARDS) and

other forms of lung injury. The landmark ARDS Network trial, which demonstrated a significant mortality reduction from 39.8% to 31.0% using a low tidal volume ventilation strategy (6 mL/kg predicted body weight vs. 12 mL/kg), is a direct application of anesthetic principles of lung-protective ventilation to the critical care setting <sup>2</sup>.

In the realm of hemodynamic management, the anesthesiologist's expertise in titrating vasoactive drugs, interpreting complex monitoring data, and supporting circulation under anesthesia has been seamlessly translated to the septic or cardiogenic shock patient. The paradigm-shifting Early Goal-Directed Therapy (EGDT) protocol for sepsis, while later large-scale trials have refined its universal application, emphasized the anesthesiology-centric principles of early fluid resuscitation and hemodynamic optimization to achieve specific targets for central venous pressure, mean arterial pressure, and central venous oxygen saturation.<sup>3</sup> Subsequent large-scale trials (ProCESS, ARISE, ProMISE, 2014) demonstrated that while the *principles* of early recognition, antibiotics, and hemodynamic support remain paramount, strict, protocolized EGDT does not improve mortality over more flexible, clinician-guided care <sup>3,4</sup>. This refined evidence underscores that the anesthesiologist's core competency—judiciously applying fluids, vasopressors, and inotropes to achieve adequate perfusion based on dynamic assessment—is the critical translation to modern sepsis bundles, rather than adherence to a rigid protocol <sup>4</sup>.

The knowledge of inotropes and vasopressors—their mechanisms, receptor specificities, and side effects—is a direct import from anesthetic pharmacology. For instance, the use of norepinephrine as a first-line vasopressor in septic shock is supported by robust evidence showing its superiority over dopamine, which was associated with a higher rate of arrhythmias <sup>4</sup>.

The ability to perform and interpret advanced hemodynamic monitoring, such as transesophageal echocardiography (TEE) in the ICU, is another skill set pioneered by cardiothoracic anesthesiologists that is now invaluable for the real-time assessment of ventricular function, volume status, and the diagnosis of life-threatening conditions like cardiac tamponade.

Perhaps one of the most significant and challenging legacies of anesthesia in the ICU is the management of sedation, analgesia, and delirium. The pharmacological arsenal used to ensure patient comfort and safety during mechanical ventilation is dominated by drugs whose properties are intimately understood by anesthesiologists: propofol, benzodiazepines, dexmedetomidine, and opioid analgesics. The shift in sedation paradigms from deep, continuous sedation to a lighter, "daily wake-up" approach was a direct result of critical care research often led by intensivists with anesthetic training. The landmark

trial by *Kress et al.* demonstrated that a daily interruption of sedative infusions decreased the median duration of mechanical ventilation from 7.3 days to 4.9 days and reduced the median ICU length of stay from 9.9 days to 6.4 days <sup>5</sup>.

This represents a reduction in ventilator days of approximately 33% and a 35% reduction in ICU stay, highlighting the profound impact of refined sedation protocols on patient outcomes and resource utilization. Furthermore, the introduction of alpha-2 agonists like dexmedetomidine, familiar to anesthesiologists for their sympatholytic and sedative properties, has provided a valuable tool for achieving cooperative sedation without significant respiratory depression, reducing the incidence of delirium compared to benzodiazepine-based regimens <sup>6</sup>. The role of anesthesiologists as perioperative physicians has also forged a critical link between the OR and the ICU, particularly in the care of the high-risk surgical patient. The concept of "Post-Operative Intensive Care" is a natural extension of anesthetic management. Anesthesiologists are leading the development of Enhanced Recovery After Surgery (ERAS) protocols, which are multidisciplinary care pathways designed to maintain physiological function and reduce the surgical stress response. Implementation of ERAS protocols has been shown to reduce postoperative complications by up to 50% and shorten hospital length of stay by 30-50%, significantly impacting the demand for critical care resources <sup>7</sup>.

For the most complex cases, the model of the "ICU Liaison" or "Perioperative Anesthesiologist" ensures a seamless transition of care, where the anesthesiologist who understands the nuances of the surgical procedure and the patient's physiological reserve continues their management into the postoperative period. This continuity is crucial, as studies indicate that failure to rescue deteriorating surgical patients is a key driver of mortality, and early intervention by clinicians skilled in resuscitation can dramatically improve outcomes <sup>8</sup>.

Finally, the impact of anesthesiology extends beyond clinical techniques to the very structure and safety culture of the ICU. Anesthesiologists introduced the principles of crisis resource management (CRM) from aviation into medicine, emphasizing teamwork, communication, and the use of cognitive aids in high-stakes environments. The implementation of checklists for procedures like central line insertion, directly modeled on the WHO Surgical Safety Checklist, has been shown to reduce the rate of catheter-related bloodstream infections (CLABSI) by over 50% in some studies <sup>9</sup>.

### **Physiological Effects of Anesthesia on Critically Ill Patients:**

Anesthetic agents primarily exert their desired CNS effects by enhancing inhibitory neurotransmission (via

GABAA receptors or alpha-2 adrenoceptors) and suppressing excitatory neurotransmission (via NMDA receptors). While this produces the therapeutic states of unconsciousness and amnesia, the consequences in the critically ill are profound. A primary concern is the alteration of cerebral autoregulation, the brain's intrinsic ability to maintain constant blood flow despite changes in systemic blood pressure. Most intravenous anesthetics, such as propofol and barbiturates, cause a dose-dependent reduction in cerebral metabolic rate (CMRO<sub>2</sub>) and a coupled decrease in cerebral blood flow (CBF)<sup>10</sup>. This can be protective in patients at risk of ischemic brain injury, such as following a cardiac arrest or traumatic brain injury (TBI). In contrast, volatile anesthetics can uncouple this relationship, potentially increasing CBF while decreasing CMRO<sub>2</sub>, which may elevate intracranial pressure (ICP) in susceptible patients<sup>11</sup>.

Perhaps the most significant long-term CNS effect is the association between anesthesia and postoperative delirium (POD) and cognitive dysfunction (POCD). Critically ill patients are exquisitely vulnerable. Benzodiazepines, once a mainstay of sedation, are now strongly linked to an increased risk of delirium. A seminal study found that for every additional milligram of lorazepam administered, the risk of delirium increased by 20% (OR 1.2, 95% CI 1.1–1.4)<sup>6</sup>. In contrast, dexmedetomidine, an alpha-2 agonist, has demonstrated a favorable profile, showing a lower incidence of delirium compared to midazolam (dexmedetomidine 54% vs midazolam 76.6%; P = 0.001) in mechanically ventilated patients<sup>12</sup>. The mechanism is multifactorial, involving the preservation of natural sleep architecture and non-GABAergic pathways, highlighting how the choice of anesthetic technique directly influences a major determinant of ICU morbidity.

The cardiovascular effects of anesthesia are arguably the most immediately life-threatening in the critically ill shown in table (1). The majority of anesthetic

agents produce direct myocardial depression and vasodilation, leading to a fall in cardiac output and systemic vascular resistance (SVR). In a patient with septic or cardiogenic shock, this can be catastrophic. Propofol, while excellent for rapid titration, is a potent vasodilator and negative inotrope. A single bolus for induction can decrease mean arterial pressure (MAP) by 20–40%, a dangerous prospect for a patient dependent on high endogenous catecholamine drive.<sup>1</sup> Propofol exemplifies these dose-dependent risks, with an induction dose of 1.5–2.5 mg/kg typically reducing mean arterial pressure (MAP) by 25–30% and systemic vascular resistance (SVR) by 15–30% in healthy patients<sup>13</sup>. In critically ill patients with shock, this cardiovascular depression is profoundly exacerbated; even a reduced dose of 0.5–1 mg/kg can precipitate a catastrophic 30–50% decrease in MAP due to combined myocardial depression, vasodilation, and loss of compensatory sympathetic tone<sup>13</sup>.

Volatile anesthetics also contribute to hemodynamic instability. They cause a dose-dependent reduction in myocardial contractility and SVR. While modern agents like sevoflurane and desflurane are less cardiodepressant than older ones, their vasodilatory properties remain significant<sup>14</sup>. This systemic vasodilation can be particularly problematic in distributive shock states like sepsis, where SVR is already critically low. The cardiovascular profile of ketamine, an NMDA receptor antagonist, is often considered favorable in hypovolemic or septic patients due to its sympathomimetic effects, which typically support heart rate and blood pressure. However, in catecholamine-depleted patients, its direct myocardial depressant effects can be unmasked, leading to cardiovascular collapse.<sup>15</sup> This illustrates that no single agent is universally ideal, and selection must be tailored to the patient's underlying pathophysiology and volume status.

**Table 1: Cardiovascular Effects of Common Anesthetic Agents in Critically Ill Patients**<sup>7, 13, 15</sup>

Anesthetic Agent	Mechanism of Action	Primary Cardiovascular Effect
<b>Propofol</b>	GABA <sub>A</sub> agonist	↓ SVR (marked vasodilation), ↓ Contractility
<b>Midazolam</b>	GABA <sub>A</sub> agonist	↓ SVR (moderate vasodilation)
<b>Dexmedetomidine</b>	Alpha-2 agonist	↓ Central sympathetic outflow (bradycardia, ↓ SVR)
<b>Sevoflurane</b>	Volatile (enhances GABA, inhibits NMDA)	↓ SVR (vasodilation), ↓ Contractility
<b>Ketamine</b>	NMDA antagonist	↑ Heart rate, ↑ Blood Pressure (via catecholamine release)
<b>Fentanyl</b>	Mu-opioid agonist	Minimal direct effect; bradycardia possible

The depressant effects of anesthesia on respiratory drive are well-known, leading to apnea and the necessity for mechanical ventilation. However, the impact extends far beyond this initial event. Anesthetics impair hypoxic pulmonary vasoconstriction (HPV), a protective mechanism that diverts blood flow from poorly ventilated lung regions. This inhibition worsens ventilation-perfusion (V/Q) mismatch, contributing to a measurable decrease in arterial oxygen tension<sup>16</sup>. Furthermore, nearly all sedative and opioid agents reduce functional residual capacity (FRC) and promote atelectasis, creating a substrate for nosocomial pneumonia.

The interaction between anesthesia and mechanical ventilation is a critical interface. The sedative and paralytic agents used by anesthesiologists facilitate the implementation of lung-protective ventilation strategies, which are paramount for managing Acute Respiratory Distress Syndrome (ARDS). As established by the ARDS Network, low tidal volume ventilation (6 mL/kg predicted body weight) reduces mortality from 39.8% to 31.0% compared to traditional volumes (12 mL/kg)<sup>2</sup>. This 22% relative risk reduction is only achievable with adequate sedation, often provided by anesthetic drugs. However, a significant challenge is the "double-edged sword" of neuromuscular blocking agents (NMBAs). While a 48-hour infusion of cisatracurium in early, severe ARDS was shown to improve adjusted 90-day survival and increase ventilator-free days without increasing muscle weakness<sup>17</sup>, the prolonged use of NMBAs is independently associated with critical illness polyneuropathy/myopathy (CIP/CIM). This underscores the need for vigilant monitoring and the use of peripheral nerve stimulators to guide dosing, a practice championed by anesthesiologists.

The renal effects of anesthesia are primarily indirect, mediated through changes in cardiovascular function. A decrease in MAP below the renal autoregulatory threshold (approximately 80 mmHg) can lead to acute kidney injury (AKI) by reducing renal blood flow and glomerular filtration rate (GFR). This is exacerbated by the release of vasopressin and activation of the sympathetic nervous system and renin-angiotensin-aldosterone system (RAAS) in response to surgical stress. Certain agents have specific concerns; sevoflurane degradation by carbon dioxide absorbents can produce Compound A, which is nephrotoxic in rodent models, though its clinical significance in humans remains debated<sup>18</sup>.

The liver, as the primary site of drug metabolism, is central to the termination of anesthetic effects. Critically ill patients with hepatic dysfunction (e.g., from shock, congestion, or pre-existing cirrhosis) exhibit profoundly altered pharmacokinetics. The metabolism of drugs like

fentanyl, midazolam, and propofol is significantly prolonged, leading to drug accumulation, prolonged sedation, and delayed awakening<sup>19</sup>. This can confound neurological assessments and unnecessarily extend the duration of mechanical ventilation and ICU stay. Conversely, anesthetics can impact hepatic blood flow. All volatile anesthetics and most intravenous agents reduce hepatic arterial and portal venous blood flow in a dose-dependent manner, which can potentially exacerbate ischemic liver injury in patients with borderline perfusion<sup>20</sup>.

### **Sedation and Analgesia:**

Historically, the default approach to managing mechanically ventilated patients was to maintain them in a deeply sedated state, often using continuous infusions of benzodiazepines. This practice was believed to ensure safety, prevent device removal, and minimize psychological distress. However, seminal research revealed the profound drawbacks of this approach. The landmark trial by **Kress *et al.*** demonstrated that a daily interruption of sedative infusions, allowing patients to awaken, led to a dramatic reduction in the duration of mechanical ventilation (4.9 days vs. 7.3 days) and ICU length of stay (6.4 days vs. 9.9 days)<sup>5</sup>. This represented a 33% reduction in time on the ventilator, fundamentally changing ICU practice. Subsequent large-scale studies confirmed that a protocolized strategy targeting light sedation (e.g., a Richmond Agitation-Sedation Scale [RASS] score of 0 to -2) improves outcomes, including fewer ventilator days and lower incidence of tracheostomy, compared to deeper sedation<sup>21</sup>.

This evidence has given rise to the "analgesia-first" paradigm, formalized in the 2018 SCCM Pain, Agitation/Sedation, Delirium, Immobility, and Sleep (PADIS) Guidelines (**Devlin *et al.***)<sup>14</sup>. These guidelines advocate for prioritizing scheduled analgesia (e.g., opioids, regional techniques) to manage discomfort, thereby minimizing the need for continuous sedative infusions. This approach aligns with the eCASH (early Comfort using Analgesia, minimal Sedatives, and maximal Humane care) model, which promotes lighter sedation targets (e.g., RASS 0 to -1), daily sedation interruption, and a focus on patient communication and early mobilization to improve outcomes such as ventilator-free days and reduce the incidence of delirium. This approach posits that pain is a primary source of distress and agitation; therefore, the first step in managing an uncomfortable patient is to ensure adequate analgesia. Opioids like fentanyl or hydromorphone are the cornerstone of this strategy. By effectively treating pain first, the requirement for sedative-hypnotics is often significantly reduced, mitigating their side effects.<sup>22</sup> This philosophy is now embedded in international guidelines,

which strongly recommend that sedation should be titrated to a predefined target level using a validated scale and that analgesia should be prioritized before the addition of sedative agents <sup>23</sup>.

The selection of sedative and analgesic agents is critical, as each class carries a distinct risk-benefit profile.

**Analgesics:** Opioids remain the primary therapy for moderate-to-severe pain in the ICU. However, they are not without risk. Side effects include respiratory depression, ileus, and tolerance—a pharmacological state requiring increasing doses to achieve the same effect. With prolonged use (typically >7 days), physical dependence develops, placing patients at high risk for opioid withdrawal syndrome upon discontinuation <sup>24</sup>.

**Sedatives:** The choice of sedative has been radically informed by outcomes research.

- **Propofol:** A GABA agonist, is favored for its rapid onset and short context-sensitive half-life, making it ideal for rapid titration and weaning. Its limitations include dose-dependent hypotension and the risk of propofol-related infusion syndrome (PRIS), a rare but fatal condition characterized by metabolic acidosis,

rhabdomyolysis, and cardiac failure, particularly with high-dose, prolonged infusions <sup>25</sup>.

- **Benzodiazepines:** Once the workhorse of ICU sedation, drugs like midazolam and lorazepam are now used more sparingly. Robust evidence links them to an increased risk and duration of delirium. The landmark MENDS trial found that lorazepam was an independent risk factor for daily transition to delirium (OR 1.2 per mg dose) <sup>18</sup>. Their long context-sensitive half-life, especially in critically ill patients, can lead to drug accumulation and prolonged ventilation.
- **Dexmedetomidine:** This alpha-2 adrenergic receptor agonist has become a first-line sedative for many patients due to its unique "cooperative sedation" profile, which allows patients to be sedated but easily rousable. It lacks significant respiratory depression, making it suitable for non-intubated patients or during ventilator weaning. Crucially, multiple trials, including SEDCOM and MENDS II, have demonstrated that dexmedetomidine reduces the prevalence and duration of delirium compared to benzodiazepines <sup>25 26</sup>. Table (2) shows comparison of primary sedative agents in the ICU as follows:

**Table 2: Comparison of Primary Sedative Agents in the ICU** <sup>24- 26</sup>

Agent	Mechanism	Advantages	Key Disadvantages & Risks	Clinical Pearl
<b>Propofol</b>	GABA_A agonist	Rapid onset/offset; Easy titration	Hypotension; PRIS (with high doses >4-5 mg/kg/hr)	First-line for rapid control and weaning; monitor triglycerides.
<b>Benzodiazepines</b>	GABA_A agonist	Reliable amnesia; Inexpensive	<b>Delirium;</b> Prolonged duration; Active metabolites	Avoid as first-line; use for specific indications (e.g., alcohol withdrawal, seizures).
<b>Dexmedetomidine</b>	Alpha-2 agonist	Cooperative sedation; No respiratory depression; Reduces delirium	Bradycardia; Hypertension (bolus); Hypotension	Ideal for light sedation, weaning, and delirium-prone patients.

Effective management is impossible without objective assessment. The use of validated tools is a cornerstone of modern care. For pain, the Critical-Care Pain Observation Tool (CPOT) or Behavioral Pain Scale (BPS) are recommended for non-communicative patients<sup>23</sup>. For sedation, the RASS or Sedation-Agitation Scale (SAS) provide a common language for titrating therapy to a specific goal. For delirium, the Confusion Assessment Method for the ICU (CAM-ICU) is the gold standard for diagnosis.

Protocols that bundle these elements—combining daily sedation interruption, spontaneous breathing trials, delirium monitoring, and early mobility (the "ABCDE bundle")—have been shown to be synergistic. Implementing such bundles has been associated with significant improvements, including a 50% increase in the odds of mobilizing patients and a 30% reduction in the risk of delirium<sup>27</sup>.

Finally, the ICU team must be vigilant for iatrogenic harm. As mentioned, prolonged infusion of opioids and benzodiazepines leads to physical dependence. **Iatrogenic Withdrawal Syndrome (IWS)** is a common and distressing problem, with an incidence as high as 32% for opioids and 29% for benzodiazepines in pediatric populations, and a significant issue in adults<sup>28</sup>. Symptoms include agitation, tremors, diarrhea, and autonomic instability, which can be mistaken for delirium and lead to re-escalation of sedatives. Prevention through the use of the lowest effective dose for the shortest duration and proactive, protocolized weaning schedules is the best strategy. The use of validated withdrawal assessment tools, such as the Withdrawal Assessment Tool-Version 1 (WAT-1), can guide symptom-triggered therapy with longer-acting agents like methadone or phenobarbital<sup>29</sup>.

### Impact of Anesthesia on Outcomes in Critically Ill Patients:

As illustrated in table (3), the choice of sedative agent has been directly linked to survival. The landmark SEDCOM trial demonstrated a significant mortality benefit with dexmedetomidine compared to midazolam, with a 28-day mortality of 22.8% in the dexmedetomidine group versus 25.4% in the midazolam group, despite similar levels of sedation<sup>24</sup>. This finding was reinforced by a meta-analysis showing a reduction in mortality with dexmedetomidine over other sedatives, particularly in the cardiac and post-surgical ICU populations<sup>25</sup>. Conversely, the use of benzodiazepines has been consistently associated with worse outcomes. A prospective cohort study found that lorazepam was an independent risk factor for transition to delirium, which itself is an independent predictor of higher 6-month mortality<sup>18</sup>.

Beyond sedation, the impact of anesthetic management on perioperative morbidity is profound. The implementation of Enhanced Recovery After Surgery (ERAS) protocols, which are multidisciplinary pathways heavily influenced by anesthesiologists (encompassing optimal fluid management, multimodal analgesia, and early mobilization), has demonstrated significant improvements in outcomes. A large meta-analysis showed that ERAS protocols reduce postoperative complications by up to 50% and shorten hospital length of stay by 30-50%<sup>7</sup>. This directly impacts critical care by reducing the influx of patients with major postoperative complications, such as pneumonia and anastomotic leaks, which require ICU resources. Furthermore, intraoperative hemodynamic management is crucial. The failure to rescue unstable surgical patients is a key driver of mortality variance between hospitals, and anesthetic vigilance in early identification and treatment of hypotension and hypoperfusion is a critical determinant of survival<sup>8</sup>.

**Table 3: Anesthetic Factors Influencing Major Morbidity and Mortality in the Critically Ill**<sup>7,18, 24, 26</sup>

Factor	Impact on Outcome	Supporting Evidence
<b>Benzodiazepine Sedation</b>	↑ Mortality, ↑ Duration of Delirium, ↑ Ventilator Days	SEDCOM, MENDS trials; Cohort studies showing independent risk. <sup>18 24</sup>
<b>Dexmedetomidine Sedation</b>	↓ Mortality (in some populations), ↓ Delirium Duration	SEDCOM trial; Various meta-analyses. <sup>24 25</sup>
<b>Deep Sedation Strategy</b>	↑ Mortality, ↑ Ventilator Days, ↑ ICU LOS	Multiple RCTs and cohort studies (e.g., <b>Kress et al.</b> ) <sup>5</sup>
<b>Implementation of ERAS</b>	↓ Postoperative Complications by ~50%, ↓ Hospital LOS by 30-50%	Large-scale meta-analyses. <sup>7</sup>
<b>Intraoperative Hypotension</b>	↑ Risk of Acute Kidney Injury, Myocardial Injury	Cumulative evidence from observational and interventional studies. <sup>26</sup>

The link between anesthesia, sedation, and delirium is one of the most robust in critical care outcomes research. Delirium is not merely a transient confusion; it is an independent predictor of death, prolonged hospitalization, and long-term cognitive impairment. As previously noted, the choice of sedative is a major modifiable risk factor. The MENDS trial found that patients receiving dexmedetomidine had more delirium-free and coma-free days compared to those receiving lorazepam (median 7 days vs. 3 days)<sup>27</sup>. This translates to a tangible improvement in neurological outcome. The pathophysiology is multifactorial, involving cholinergic deficiency and uninhibited inflammation, which are differentially affected by GABAergic agents like benzodiazepines versus alpha-2 agonists like dexmedetomidine.

The impact extends beyond the ICU stay. The concept of Post-ICU Syndrome (PICS), which includes long-term cognitive impairment, is increasingly recognized. Patients who experience delirium during their ICU stay are at significantly higher risk for long-term cognitive deficits resembling moderate traumatic brain injury or mild Alzheimer's disease<sup>28</sup>.

The duration of mechanical ventilation is a key performance metric in the ICU, directly impacting the risk of ventilator-associated pneumonia (VAP), ICU length of stay, and cost. Anesthetic management is a primary determinant of this outcome. The strategy of daily sedation interruption, as pioneered by *Kress et al.*, reduced the median duration of mechanical ventilation by 2.4 days (33%)<sup>5</sup>. When combined with spontaneous breathing trials (the "Awakening and Breathing Controlled" or ABC trial), this paired protocol further reduced time on the ventilator, with patients in the intervention group spending a median of 14.7 days breathing without assistance in the first 28 days, compared to 11.6 days in the control group<sup>29</sup>. This represents a 27% improvement in ventilator-free living.

The use of neuromuscular blocking agents (NMBAs) in severe ARDS presents a complex outcome picture. The ACURASYS trial showed that a 48-hour infusion of cisatracurium in early, severe ARDS ( $\text{PaO}_2/\text{FiO}_2 < 150$ ) increased adjusted 90-day survival (Hazard Ratio for death 0.68) and increased ventilator-free days<sup>30</sup>. However, this benefit must be balanced against the known risk of NMBA-associated weakness, which can prolong rehabilitation. This illustrates a critical outcome trade-off where anesthetic intervention improves survival but may transiently impair functional recovery, requiring careful patient selection.

The ultimate goal of critical care is to return patients to their functional baseline. Anesthetic interventions play a significant role in this process. The early and effective management of pain is crucial. Uncontrolled pain is a

barrier to mobilization and can lead to the development of chronic post-ICU pain syndromes. Multimodal analgesia, an anesthetic concept involving the use of non-opioid adjuncts (e.g., acetaminophen, NSAIDs, gabapentinoids, regional anesthesia), reduces opioid consumption and its associated side effects like ileus and sedation, thereby facilitating earlier physical therapy and mobilization<sup>31</sup>.

Early mobilization in the ICU is a powerful predictor of functional recovery. The seminal study by *Schweickert et al.* demonstrated that early physical and occupational therapy during daily sedation interruptions resulted in a return to independent functional status at hospital discharge in 59% of patients, compared to only 35% in the control group<sup>32</sup>. This dramatic improvement in functional outcome is entirely dependent on an anesthetic strategy that minimizes sedative exposure and prioritizes patient wakefulness and cooperation. Without the foundational principle of light or interruptible sedation, early mobilization is impossible to implement effectively.

### Perioperative Considerations in the Management of Critical Care Patients:

The preoperative evaluation of a critically ill patient is not about "clearance" but about risk stratification, active optimization, and shared decision-making. This process must be highly efficient, as time is often limited. A focused assessment should evaluate the patient's current physiological state, including volume status, cardiovascular performance, respiratory function, and end-organ perfusion. Key objectives in table (4) include:

- **Hemodynamic Optimization:** The concept of "fit for surgery" involves ensuring adequate tissue perfusion. This may involve judicious fluid resuscitation, often guided by dynamic parameters like stroke volume variation, or the initiation and titration of vasoactive infusions (e.g., norepinephrine, vasopressin) to achieve a mean arterial pressure (MAP) sufficient for vital organ perfusion, typically  $>65$  mmHg<sup>33</sup>. It is not routinely recommended to stop inotropes or vasopressors precipitously for transfer to the operating room unless the patient is unstable; these infusions must be continued seamlessly, often requiring dedicated infusion pumps and lines.
- **Respiratory Preparation:** The preoperative review should include current ventilator settings, oxygenation status ( $\text{PaO}_2/\text{FiO}_2$  ratio), and the presence of dynamic hyperinflation in COPD patients. A plan for intraoperative ventilation, adhering to lung-protective principles, should be established in advance<sup>34</sup>.
- **Multidisciplinary Communication:** A formal "time-out" or briefing involving the intensivist,

surgeon, and anesthesiologist is paramount. This discussion should clarify the surgical goals, the anticipated physiological challenges, the plan for vasoactive support and ventilation, and, crucially, the postoperative plan. Will the patient return to the ICU intubated? What are the hemodynamic targets? Establishing these parameters preemptively mitigates handover errors and aligns the entire team <sup>35</sup>.

The intraoperative phase is an extension of ICU care, with the added physiological insults of surgical trauma and anesthesia. The anesthetic plan must be tailored to the patient's critical illness.

- **Hemodynamic Management:** Goal-directed therapy (GDT) should be employed, utilizing advanced hemodynamic monitoring such as arterial waveform analysis or transesophageal echocardiography (TEE). The key is to move beyond simple blood pressure targets and optimize flow. Studies have shown that GDT in high-risk surgical patients can reduce postoperative complications by up to 25-50% <sup>36</sup>. The avoidance of intraoperative hypotension is critical, as even short periods of MAP below 65 mmHg are associated with an increased risk of acute kidney injury and myocardial injury <sup>26</sup>.
- **Ventilatory Strategy:** The principles of lung-protective ventilation are non-negotiable. This

includes using low tidal volumes (6-8 mL/kg predicted body weight), titrating positive end-expiratory pressure (PEEP) to prevent alveolar collapse, and using recruitment maneuvers judiciously <sup>37</sup>. The FIO<sub>2</sub> should be titrated to maintain adequate oxygenation (SpO<sub>2</sub> 92-96%) to avoid absorptive atelectasis and oxygen toxicity. For patients with severe ARDS, intraoperative ventilation may require advanced modes identical to those used in the ICU.

- **Analgesia and Anesthetic Technique:** A multimodal analgesia regimen is the cornerstone of management. This reduces opioid consumption and its associated side effects, including ileus, respiratory depression, and tolerance. Techniques should include regional anesthesia (e.g., epidural, fascial plane blocks) where appropriate, and scheduled non-opioid analgesics such as acetaminophen, NSAIDs (if renal function allows), and adjuncts like ketamine or lidocaine infusions <sup>38</sup>. The choice of induction and maintenance agents must account for hemodynamic instability. Etomidate or ketamine may be preferred for induction in shock states, while a balanced technique using low-dose volatile anesthetics or TIVA with high-dose opioids is often used for maintenance.

**Table 4: Key Intraoperative Goals for the Critically Ill Surgical Patient** <sup>26, 33- 39</sup>

System	Goal	Recommended Strategy
<b>Cardiovascular</b>	Maintain end-organ perfusion	GDT with fluids & vasopressors; Avoid MAP < 65 mmHg; Continuous monitoring with arterial line <sup>26, 33</sup> .
<b>Respiratory</b>	Prevent ventilator-induced lung injury	Low Vt (6-8 mL/kg PBW); Titrated PEEP; Permissive hypercapnia if necessary <sup>34- 37</sup> .
<b>Analgesia</b>	Minimize opioid-related side effects	Multimodal regimen: Regional anesthesia, Acetaminophen, NSAIDs, Ketamine/Lidocaine infusions <sup>38</sup> .
<b>Metabolic/Hematologic</b>	Correct profound acidosis & coagulopathy	Permissive acidosis (pH >7.2); Goal-directed transfusion; Viscoelastic testing (TEG/ROTEM) to guide factor replacement <sup>39</sup> .
<b>Temperature</b>	Maintain normothermia	<b>Proactive warming:</b> Use forced-air warmers, fluid warmers, and warmed humidified gases. <b>Monitor core temperature</b> (e.g., esophageal, bladder). Avoid intraoperative hypothermia (<36°C) to reduce surgical site infection, bleeding, and morbidity <sup>39</sup> .

The conclusion of surgery is a period of high risk. A structured handover from the operating room team to the receiving ICU team is essential to prevent communication errors. This handover should occur without interruption and include a summary of the patient's preoperative status, the surgical procedure and findings, the anesthetic course (including drugs administered and difficulties encountered), current hemodynamic and ventilatory status, and the ongoing plan for resuscitation, analgesia, and monitoring<sup>35</sup>.

The decision regarding postoperative ventilation is critical. Many critically ill patients will remain sedated and ventilated. For those considered for extubation, a careful assessment of their readiness is required, considering gas exchange, mental status, hemodynamic stability, and the absence of a difficult airway. The postoperative period also demands vigilance for common complications, including acute kidney injury, transfusion-related acute lung injury (TRALI), and surgical site infections. The anesthesiologist's role in initiating and communicating a clear postoperative analgesic and sedation plan cannot be overstated, as this directly impacts the patient's ability to wean from ventilation, mobilize, and recover<sup>39</sup>.

## CONCLUSION

The influence of anesthesiology on critical care medicine is both foundational and continuously evolving. From its historical roots in postoperative recovery to its central role in modern ICU management, the specialty provides an indispensable framework for supporting patients through periods of profound physiological instability. This review has detailed how anesthetic principles directly inform essential practices in mechanical ventilation, hemodynamic support, and sedation, directly impacting patient-centered outcomes including survival, delirium incidence, and long-term functional recovery. The evidence clearly demonstrates that protocols born from anesthetic expertise—such as lung-protective ventilation, goal-directed hemodynamic therapy, and analgesia-focused light sedation—are not merely supportive measures but active interventions that reduce morbidity and mortality.

As critical care continues to advance, the integration of anesthetic knowledge will remain paramount. The future lies in further refining these practices through precision medicine, optimizing perioperative care for the most vulnerable, and mitigating the long-term consequences of critical illness. The anesthesiologist-intensivist, armed with a unique skillset in applied physiology and pharmacology, is thus essential in steering the field toward not only saving lives but also ensuring the quality of survival.

## DECLARATIONS

### Ethics Approval and Consent to Participate

Not applicable.

### Consent for Publication

Not applicable.

### Funding

None.

### Competing Interests

None.

### Authors' Contributions

All authors contributed significantly to this review article. M.H.A., B.A.S.A., and A.O.A.A. conceived the review's scope and structure. A.N.A.M.S.A., M.H.Z.H., and A.M.A. conducted the systematic literature search, data extraction, and initial synthesis. A.A.A., A.N.A., M.F.M.A., and M.H.A. contributed to drafting major sections of the manuscript, with a focus on hemodynamics, pharmacology, and ventilation strategies. M.A.A. provided critical revision for intellectual content and integration of clinical guidelines. All authors participated in the critical review, editing, and final approval of the submitted manuscript.

### Acknowledgements

None.

## REFERENCES

1. Higgs A, McGrath BA, Goddard C, Rangasami J, Suntharalingam G, Gale R, Cook TM, Society DA. Guidelines for the management of tracheal intubation in critically ill adults. *British journal of anaesthesia*. 2018 Feb 1;120(2):323-52.
2. Merola R, Vargas M, Battaglini D. Revisiting Acute Respiratory Distress Syndrome ventilation management: Time for a paradigm shift focusing on tidal volume. *Respiratory Physiology & Neurobiology*. 2025 May 30:104454.
3. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *New England journal of medicine*. 2001 Nov 8;345(19):1368-77.
4. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL. Comparison of dopamine and norepinephrine in the treatment of shock. *New England Journal of Medicine*. 2010 Mar 4;362(9):779-89.
5. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. *New England Journal of Medicine*. 2000 May 18;342(20):1471-7.

6. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. *Jama*. 2009 Feb 4;301(5):489-99.
7. Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. *JAMA surgery*. 2017 Mar 1;152(3):292-8.
8. Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with inpatient surgery. *New England Journal of Medicine*. 2009 Oct 1;361(14):1368-75.
9. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, Sexton B, Hyzy R, Welsh R, Roth G, Bander J. An intervention to decrease catheter-related bloodstream infections in the ICU. *New England journal of medicine*. 2006 Dec 28;355(26):2725-32.
10. Drummond JC. Blood pressure and the brain: how low can you go?. *Anesthesia & Analgesia*. 2019 Apr 1;128(4):759-71.
11. Persson ND, Lohela TJ, Mortensen KN, Rosenholm M, Li Q, Weikop P, Nedergaard M, Lilius TO. Anesthesia blunts carbon dioxide effects on glymphatic cerebrospinal fluid dynamics in mechanically ventilated rats. *Anesthesiology*. 2024 Jul 4;141(2):338-52.
12. Viburajah V, Selvaraj V. Comparative Evaluation of Effect of Propofol, Etomidate and a Combination of Propofol and Etomidate on the Hemodynamic Response to Induction and Endotracheal Intubation: A Prospective Randomized Double Blinded Study. *Journal of Anesthesia/Anestezi Dergisi (JARSS)*. 2024 Jan 1;32(1).
13. Ebert TJ, Harkin CP, Muzi M. Cardiovascular responses to sevoflurane: a review. *Anesthesia & Analgesia*. 1995 Dec 1;81(6S):11S-22S.
14. Devlin JW, Skrobik Y, Rochwerg B, Nunnally ME, Needham DM, Gelinas C, Pandharipande PP, Slooter AJ, Watson PL, Weinhouse GL, Kho ME. Methodologic innovation in creating clinical practice guidelines: insights from the 2018 society of critical care medicine pain, agitation/sedation, delirium, immobility, and sleep disruption guideline effort. *Critical care medicine*. 2018 Sep 1;46(9):1457-63.
15. Ballók B. *Respiratory effects of general anesthesia and pulmonary embolism in rodent models* (Doctoral dissertation, szte).
16. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM. Neuromuscular blockers in early acute respiratory distress syndrome. *New England Journal of Medicine*. 2010 Sep 16;363(12):1107-16.
17. Karim HM, Singha SK, Panda CK, Khetarpal M. Randomized, Single-Blind Comparison of Two Different Flow Rates of Sevoflurane Anesthesia on Acute Kidney Injury. *Cureus*. 2025 Mar 3;17(3).
18. Dalamagka MI. Remifentanyl as an anesthetic agent in children.
19. Foong KW, Chaw SH, Lo YL, Loh PS. Population pharmacokinetics of intravenous lidocaine in adults: a systematic review. *Clinical Pharmacokinetics*. 2024 May;63(5):623-43.
20. Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, Shintani AK, Thompson JL, Jackson JC, Deppen SA, Stiles RA. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. *Jama*. 2007 Dec 12;298(22):2644-53.
21. Balas MC, Vasilevskis EE, Olsen KM, Schmid KK, Shostrom V, Cohen MZ, Peitz G, Gannon DE, Sisson J, Sullivan J, Stothert JC. Effectiveness and safety of the awakening and breathing coordination, delirium monitoring/management, and early exercise/mobility bundle. *Critical care medicine*. 2014 May 1;42(5):1024-36.
22. Best KM, Boullata JI, Curley MA. Risk factors associated with iatrogenic opioid and benzodiazepine withdrawal in critically ill pediatric patients: a systematic review and conceptual model. *Pediatric Critical Care Medicine*. 2015 Feb 1;16(2):175-83.
23. Franck LS, Scoppettuolo LA, Wypij D, Curley MA. Validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients. *Pain*. 2012 Jan 1;153(1):142-8.
24. Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. *Survey of Anesthesiology*. 2014 Aug 1;58(4):184-5.
25. Paramsothy J, Gutlapalli SD, Ganipineni VDP, Mulango I, Okorie IJ, Arrey Agbor DB, Delp C, Apple H, Kheyson B, Nfonoyim J, Isber N, Yalamanchili M. Propofol in ICU Settings: Understanding and Managing Anti-Arhythmic, Pro-Arhythmic Effects, and Propofol Infusion Syndrome. *Cureus*. 2023 Jun 15;15(6):e40456. doi: 10.7759/cureus.40456. PMID: 37456460; PMCID: PMC10349530.
26. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, Brummel NE, Hughes CG, Vasilevskis EE, Shintani AK, Moons KG. Long-term cognitive impairment after critical illness. *New England Journal of Medicine*. 2013 Oct 3;369(14):1306-16.
27. Girard TD, Kress JP, Fuchs BD, Thomason JW, Schweickert WD, Pun BT, Taichman DB, Dunn JG, Pohlman AS, Kinniry PA, Jackson JC. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. *The Lancet*. 2008 Jan 12;371(9607):126-34.
28. Alhazzani W, Alshahrani M, Jaeschke R, Forel JM, Papazian L, Sevransky J, Meade MO. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. *Critical care*. 2013 Mar 11;17(2):R43.
29. Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJ, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep

- disruption in adult patients in the ICU. *Critical care medicine*. 2018 Sep 1;46(9):e825-73.
30. Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, Spears L, Miller M, Franczyk M, Deprizio D, Schmidt GA. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. *The Lancet*. 2009 May 30;373(9678):1874-82.
  31. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, Jaeschke R, Mebazaa A, Pinsky MR, Teboul JL, Vincent JL. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. *Intensive care medicine*. 2014 Dec;40(12):1795-815.
  32. Parry SM, Nydahl P, Needham DM. Implementing early physical rehabilitation and mobilisation in the ICU: institutional, clinician, and patient considerations. *Intensive care medicine*. 2018 Apr;44(4):470-3.
  33. Segall N, Bonifacio AS, Schroeder RA, Barbeito A, Rogers D, Thornlow DK, Emery J, Kellum S, Wright MC, Mark JB. Can we make postoperative patient handovers safer? A systematic review of the literature. *Anesthesia & Analgesia*. 2012 Jul 1;115(1):102-15.
  34. Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. *Anesthesia & analgesia*. 2011 Jun 1;112(6):1392-402.
  35. Neto AS, Cardoso SO, Manetta JA, Pereira VG, Espósito DC, Pasqualucci MD, Damasceno MC, Schultz MJ. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis. *Jama*. 2012 Oct 24;308(16):1651-9.
  36. Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review. *JAMA surgery*. 2017 Jul 1;152(7):691-7.
  37. Bolliger D, Goerlinger K, Tanaka KA, Warner DS. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. *Anesthesiology*. 2010 Nov 1;113(5):1205-19.
  38. Forbes SS, Eskicioglu C, Nathens AB, Fenech DS, Laflamme C, McLean RF, McLeod RS, Best Practice in General Surgery Committee. Evidence-based guidelines for prevention of perioperative hypothermia. *Journal of the American College of Surgeons*. 2009 Oct 1;209(4):492-503e1.
  39. Brill JB, Brenner M, Duchesne J, Roberts D, Ferrada P, Horer T, et al. The role of TEG and ROTEM in damage control resuscitation. *Shock*. 2021 Dec 1;56(1S):52-61.